DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1alpha to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases[1][2][3].
Molecular Weight:
2424.85
Formula:
C108H170N34O26S2
Target:
CXCR,Dengue Virus
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
